Grey Peptides News Desk

About the News Desk

The Grey Peptides News Desk is the editorial team responsible for the site's news coverage — regulatory action by the FDA and EMA, clinical-trial readouts, pipeline announcements, and industry developments that affect peptide therapy and research. The News Desk operates under the same editorial standards as the rest of Grey Peptides: no commercial bias, no vendor relationships, no sponsored posts.

We use an organization byline rather than individual author names for news coverage because most of these posts are short, time-sensitive summaries of public regulatory or trial events. The editorial work is collective: a writer drafts, a second editor verifies sources and facts, and a third reviews the framing for accuracy and tone before publication. Where coverage involves substantive analysis or evidence interpretation, that work is published under an individual author byline in the articles section instead.

What we cover

• FDA regulatory action — approvals, label expansions, warning letters, compounding policy, advisory-committee meetings, and Federal Register notices.
• Clinical trial readouts — phase 2/3 topline announcements from sponsors, full publications in peer-reviewed journals, and conference presentations (ADA, ECO, EASD, ENDO).
• Pipeline developments — investigational compounds entering or exiting key trial phases, regulatory submissions, and breakthrough designations.
• EMA, MHRA, and Health Canada action where it materially affects the peptide landscape.
• Industry developments — manufacturing capacity, supply, generic launches, and major commercial agreements that affect patient access.

Sourcing standards

Every news post on Grey Peptides traces back to a primary source — typically an FDA press release, a company press release from an SEC-registered or EMA-listed entity, a peer-reviewed journal article, a conference presentation, or first-hand reporting from one of the established pharma news outlets we read (STAT, Endpoints, Reuters, BioSpace, Pharmacy Times, AJMC, Medscape, FierceBiotech).

We paraphrase. We do not republish. Quotes from sources are kept short and used only where the exact wording carries legal or scientific weight that paraphrasing would lose. Every news post links to its source so readers can verify the original reporting and read further.

What we don't do

We don't cover stock-market speculation, analyst price targets, or commentary on share price movements as news. We don't cover product launches from peptide vendors or compounding pharmacies. We don't write about "trends" in social-media discourse around peptides. The News Desk exists to report on regulatory and clinical reality, not market sentiment.

Corrections

If a news post misstates a fact, mischaracterizes a study, or links to a source that has been retracted or substantially updated, contact editors@greypeptides.com. Material corrections are made promptly and disclosed at the bottom of the affected post with a dated correction note.

Editorial independence

Grey Peptides has no advertisers, no affiliate relationships with peptide vendors or compounding pharmacies, and no commercial sponsors. The News Desk operates with the same independence as the rest of the site. We cover companies (Eli Lilly, Novo Nordisk, Amgen, Pfizer, Roche) because their actions shape what's available to patients and researchers — not because we have any relationship with them.